Treatment for advanced lung cancer with specific gene changes after targeted therapy and chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment for advanced non-small cell lung cancer that has certain gene changes (like ALK, EGFR, or ROS1) and has already been treated with targeted therapy and chemotherapy. It aims to find out if the study drug can help when previous treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer with a specific gene change (such as ALK, EGFR, HER2, MET, NTRK, RET, or ROS1) that has been treated with an approved targeted therapy.
- You must have had platinum-based chemotherapy for stage 4 or recurrent lung cancer.
- You must not have received more than 3 types of prior chemotherapy or antibody-drug conjugates for your lung cancer.
- You must have progressed (worsened) during or after your most recent cancer treatment.
- You must not have had prior treatment with a TROP2-targeting drug or immunotherapy (PD-1/PD-L1 inhibitors).
- You must be in generally good health (able to do daily activities) and have adequate organ function (kidney, liver, blood counts) as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Hear when a new Recurrent Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.